Bashar Hassan

Bashar Hassan

Auto-generated profile, based on publicly available information

Bashar Hassan

Department of Plastic and Reconstructive Surgery, Center for Transgender and Gender Expansive Health, The Johns Hopkins University School of Medicine , Baltimore, MD

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2022 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
BHBashar Hassan
Bashar Hassan
YYYara Yazbeck
Yara Yazbeck
VAVanessa Akiki
Vanessa Akiki
ISIbrahim Salti
Ibrahim Salti
ATArafat Tfayli
Arafat Tfayli
Cushing’s syndrome (CS) due to ectopic adrenocorticotropic hormone (ACTH) secretion (EAS) can result from a variety of tumours and rarely from those of prostatic origin. We present a male patient in his early 60s with ACTH-secreting metastatic prostate adenocarcinoma with neuroendocrine differentiation (ICD-O code 8574/3) years after prostatectomy and androgen-deprivation therapy, initially presenting with Cushingoid features. After open radical prostatectomy and bilateral orchiectomy for disease recurrence, the patient was found to have metastatic liver and bone lesions highly suggestive of metastatic prostatic cancer. About 10% of cells on liver biopsy expressed ACTH, a finding consistent with EAS as the cause of CS. His stay was complicated with multiple infections and ultimate death. Hence, we report a case of metastatic prostate adenocarcinoma with neuroendocrine differentiation who presented with CS. We also emphasize the importance of adequate and timely treatment.

10 February 2025 in Transgender Health
Verified
Journal Article
Closed access
BHBashar Hassan
Bashar Hassan
JMJessica Mroueh
Jessica Mroueh
VMVanessa Mroueh
Vanessa Mroueh
Joseph M. EscandonJoseph M. Escandon
Joseph M. Escandon
SASafi Ali-Khan
Safi Ali-Khan
Oscar ManriqueOscar Manrique
Oscar Manrique
Purpose: In 2020, videos with the hashtag #trans had over 6 billion views on the video-sharing application “TikTok.” We aim to analyze TikTok users' engagement with gender-affirming surgery (GAS) content by transgender and nonbinary (TGNB) patients and plastic surgeons. Methods: Between August 23 through September 11, 2021, we analyzed the top 14 hashtags for GAS and the top 10 most viewed videos for each hashtag using the TikTok application. We extracted the number of shares, likes, comments, and analyzed the quality of video comments, content, and creator. Results: Transmasculine top surgery ( n =53, 37.9%) was the most featured GAS. Most videos were posted by patients ( n =104, 74.3%). Videos posted by the patients' significant other (PSO) had a significantly higher number of shares (median [interquartile range (IQR)] 17,850 [18882.5]) and lower rate of negative comments per video (Median [IQR] 0% [0%]) compared with those posted by Patients (median [IQR] 214 [868.25], p =0.045; median [IQR] 0% [5%], p =0.006) or Plastic surgeon (median [IQR] 226.5 [297.25], p =0.02; median [IQR] 5% [10%], p =0.043). Most videos presented postoperative care/results ( n =45, 32.1%) and had a significantly higher number of likes (median [IQR] 116,500 [212,700]) compared with educational videos (median [IQR] 20,700 [66,939], p =0.044) and those on TGNB awareness/pride (median [IQR] 31,050 [84226.5], p =0.034). Conclusion: TikTok users mostly engage with videos by the PSO on postoperative outcomes compared with educational and TGNB awareness/pride content posted by patients and surgeons. Adapting TikTok content may increase engagement with future patients and family members.

16 October 2024 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
BHBashar Hassan
Bashar Hassan
ASAndrew Suchan
Andrew Suchan
MBMadyson Brown
Madyson Brown
AKArman Kishan
Arman Kishan
FLFan Liang
Fan Liang
BTBrindusa Truta
Brindusa Truta
Background: Inflammatory bowel disease (IBD) is a global healthcare problem that affects around 3 million people in the United States. Although the impact of gender-affirming hormone therapy (GAHT) on IBD severity has been studied in cisgender patients, there is currently no literature on the impact of exogenous hormone therapy (HT) in transgender and nonbinary (TGNB) individuals. Methods: We conducted a retrospective chart review of TGNB adults diagnosed with IBD and treated with HT for gender dysphoria at Johns Hopkins Hospital (2015-2022). We aimed to determine whether the use of GAHT was associated with subsequent increase in IBD severity. We compared the incidence of flares before vs after GAHT. Results: Twenty-two patients were analyzed. More than half (59%) of them were assigned female at birth, identified as transmen, and underwent masculinizing HT. Their median (interquartile range) age was 30 (25-36) years. More patients had Crohn’s disease compared with ulcerative colitis (13 [59.1%] vs 9 [40.9%], P = .23) with a median IBD duration of 6.2 (1.8-12.3) years. Nine (41%) patients were on biologics. Of 15 patients on HT, 8 (36.3%) experienced at least one flare. Most of them were treated with steroids (66.7%), and 6 (40%) required hospital or emergency room admission. The proportion of patients who flared after GAHT was similar to that before GAHT: 9 (60%) vs 8 (53.3%), P = 1.0. Conclusions: GAHT was not associated with increased incidence of flares. Larger prospective randomized studies are needed to confirm our findings and understand the interaction between GAHT and IBD in TGNB individuals.

2 February 2024 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
KLKaren R. Li
Karen R. Li
CLChristian X. Lava
Christian X. Lava
MNMonique L. Bautista Neughebauer
Monique L. Bautista Neughebauer
BHBashar Hassan
Bashar Hassan
LBLauren E. Berger
Lauren E. Berger
GCGabriel Del Corral
Gabriel Del Corral

1 February 2026 in Annals of Plastic Surgery
Verified
Journal Article
Closed access
NSNawal M. Shams
Nawal M. Shams
BHBashar Hassan
Bashar Hassan
FZFerris Zeitouni
Ferris Zeitouni
TKTaylor Kolosky
Taylor Kolosky
NRNicholas Randolph
Nicholas Randolph
MGMichael P. Grant
Michael P. Grant
Purpose: Up to half of patients with traumatic optic neuropathy (TON) develop permanent vision loss. The diagnosis and management of TON are challenging. Here, we aim to identify craniofacial fractures associated with TON and compare visual outcomes in TON patients under observation versus steroid-based management. Methods: We reviewed CT scans of patients after acute facial trauma at the R Adams Cowley Shock Trauma Center from 2018 to 2022 to determine craniofacial fractures associated with TON. TON patient outcomes between 2013 and 2022 were analyzed to compare steroid treatment versus observation. Primary outcomes were improvement in visual acuity and time to improvement. Multivariate logistic and linear regressions were performed. Results: Among 2374 patients presenting with acute facial fractures between 2018 and 2022, 21 (0.9%) had TON. Sphenoid sinus fractures were associated with the greatest odds of TON (aOR [95% CI], 25 [9–68]) followed by LeFort III and naso-orbitoethmoid (NOE) fractures (aOR [95% CI], 13 [4–42] and 7 [2–24], respectively), compared with patients without these fractures. Between 2013 and 2022, treatment outcomes were analyzed in 86 TON patients (96 eyes). Their median (IQR) follow-up was 9 (4–31) months. Patients treated with IV methylprednisolone, ranging from 250 to 1000 mg for a maximum of 3 days, were more likely to have improvement in visual acuity compared to those managed with observation (8/13 [62%], 27/83 [33%], P < 0.05). Steroids were also associated with a 57-day quicker improvement in visual acuity compared to observation ( B = −57.1, P = 0.007). Conclusion: Patients with sphenoid sinus fractures should be carefully examined for the presence of a TON. At our institution, steroid therapy results in a more rapid improvement and a better final visual acuity than observation in patients with TON.

16 December 2025 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
ASAndrew Suchan
Andrew Suchan
LCLara Chaaban
Lara Chaaban
LKLynn Kobeissi
Lynn Kobeissi
BHBashar A Hassan
Bashar A Hassan
FLFan Liang
Fan Liang
JMJoanna M Melia
Joanna M Melia
Background: Transgender and nonbinary (TGNB) individuals comprise 0.5% to 0.6% of the U.S. population and face significant healthcare disparities, yet little is known about inflammatory bowel disease (IBD) in this group. We aimed to characterize IBD prevalence, comorbidities, healthcare utilization, and the impact of hormone replacement therapy (HRT) in TGNB individuals. Methods: Using TriNetX, we analyzed (1) IBD prevalence among TGNB adults, (2) comparisons of IBD patients who are and who are not TGNB, and (3) comparisons of TGNB IBD patients with and without HRT. Outcomes included demographics, comorbidities, laboratory markers, healthcare encounters, IBD treatment, and cardiovascular and thrombotic events. Results: Of 111 227 TGNB patients, prevalence of Crohn’s disease and ulcerative colitis was 0.508% and 0.448%, respectively, increasing with age. TGNB patients were younger (32.5 years of age vs 46.9 years of age; P < .001), exhibited higher rates of gastrointestinal and psychiatric comorbidities, and had more outpatient, emergency, and hospital visits, yet they underwent fewer endoscopies (25.7% vs 30.7% risk; P = .011) and were less likely to receive targeted IBD therapy than cisgender patients. Patients with HRT had more outpatient encounters (66.7% vs 58.2%; P = .010) and were more likely to use therapies like mesalamine (12.4% vs 7.6%; P = .021) than those without HRT. There were no significant differences in laboratory markers or thrombotic or cardiovascular events in these analyses. Conclusions: TGNB IBD patients experience greater gastrointestinal and psychiatric comorbidities and receive fewer interventions overall despite greater healthcare contact. HRT was not associated with worsening disease or complications. These findings highlight critical disparities and the need for further research in this population.